Talaris Therapeutics, Inc. – NASDAQ:TALS

Add to watchlist

Market closed

Open in 3 days

-6.85%

month

+14.77%

quarter

+12.40%

year

Market Cap	116.44M
Enterprise value	49.99M

P/E	-0.20
EV/Sales	N/A
EV/EBITDA	-1.08
Price/Sales	N/A
Price/Book	0.08
PEG ratio	N/A
EPS	-13.73

Revenue	N/A
EBITDA	-46.14M
Income	-57.65M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Talaris Therapeutics, Inc. (NASDAQ:TALS): Profit margin
Dec 2022	0	-14.98M
Mar 2023	0	-20.91M
Jun 2023	0	-14.73M
Sep 2023	0	-7.01M

Talaris Therapeutics, Inc. (NASDAQ:TALS): Earnings per share (EPS)
2023-05-15	0.35	-0.54
2023-06-29	0.35	-0.45
2023-08-14	-0.15	-0.2

Talaris Therapeutics, Inc. (NASDAQ:TALS): Debt to assets
Dec 2022	193715000	13.66M	7.05%
Mar 2023	172607000	10.87M	6.3%
Jun 2023	159121000	10.68M	6.72%
Sep 2023	151061000	8.18M	5.42%

Talaris Therapeutics, Inc. (NASDAQ:TALS): Cash Flow
Dec 2022	-13.87M	9.01M	60
Mar 2023	-16.90M	27.41M	46K
Jun 2023	-14.67M	8.91M	137K
Sep 2023	-7.01M	0	0

Talaris Therapeutics alternative data

Talaris Therapeutics
Employees

Talaris Therapeutics, Inc. (NASDAQ:TALS): Employee count
Aug 2023	84
Sep 2023	84
Oct 2023	84
Nov 2023	84
Dec 2023	84
Jan 2024	84
Feb 2024	84
Mar 2024	84
Apr 2024	84
May 2024	84
Jun 2024	84
Jul 2024	84

Talaris Therapeutics
Hedge Funds Holdings Q1 2023

20.63% -44.23%

of TALS is owned by hedge funds

29 -24

hedge funds hold TALS stock

8.50M -18.32M

shares is hold by hedge funds

TALS hedge funds holdings changes

Talaris Therapeutics
Insider Trading

Talaris Therapeutics, Inc. (NASDAQ:TALS): Insider trades (number of shares)
Period	Buy	Sel
Feb 2023	0	10051
Mar 2023	0	27707
Apr 2023	0	232729
Jun 2023	0	250003
Oct 2023	27800	0
Nov 2023	5000	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Purchase	17 Nov 2023	THIARA PARVINDER director director	Common Stock	1,000	$17.31	$17,310
Purchase	17 Nov 2023	KULKARNI SANDEEP CHIDAMBAR director, officer: CEO director, officer: CEO	Common Stock	4,000	$16.99	$67,960
Purchase	27 Oct 2023	CASTELEIN CALEY director director	Common Stock	15,800	$14.55	$229,890
Purchase	26 Oct 2023	KULKARNI SANDEEP CHIDAMBAR director, officer: CEO director, officer: CEO	Common Stock	5,000	$12.25	$61,250
Purchase	25 Oct 2023	THIARA PARVINDER director director	Common Stock	2,000	$12.12	$24,240
Purchase	24 Oct 2023	THIARA PARVINDER director director	Common Stock	5,000	$10.66	$53,300
Sale	14 Jun 2023	ILDSTAD SUZANNE director	Common Stock	12,942	$2.49	$32,239
Sale	13 Jun 2023	ILDSTAD SUZANNE director	Common Stock	14,208	$2.56	$36,344
Sale	12 Jun 2023	ILDSTAD SUZANNE director	Common Stock	16,870	$2.59	$43,727
Sale	9 Jun 2023	ILDSTAD SUZANNE director	Common Stock	25,419	$2.46	$62,632

TALS insider trading transactions

Talaris Therapeutics
Executives

Insider	Age	Compensation
Mr. Scott Requadt J.D., L.L.B., M.B.A., MBA (1968) Pres, Chief Executive Officer, Sec. & Director	57	$544,760
Dr. Suzanne T. Ildstad M.D. (1953) Founder, Chief Scientific Officer & Director	72	$486,070
Ms. Nancy Krieger M.D. (1967) Chief Medical Officer	58	$482,760

Talaris Therapeutics
Latest News

Thursday, 19 October 2023
17:37	Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Placement of $75 Million	globenewswire.com
Tuesday, 17 October 2023
17:47	Talaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline Bio	globenewswire.com
Friday, 6 October 2023
17:09	Talaris Therapeutics Declares Special Dividend In Connection with Proposed Merger with Tourmaline Bio	globenewswire.com
Wednesday, 4 October 2023
08:30	New York Blood Center Enterprises Acquires Commercial-Scale Cell & Gene Therapy Development and Manufacturing Facilities from Talaris Therapeutics	globenewswire.com
Thursday, 28 September 2023
14:47	TALARIS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Talaris Therapeutics, Inc. - TALS	businesswire.com
Monday, 26 June 2023
15:40	3 Hot Penny Stocks to Watch Before Next Week	PennyStocks
Friday, 21 October 2022
12:48	Talaris (TALS) Down on Patient Death From Renal Transplant Study	Zacks Investment Research
Thursday, 20 October 2022
08:24	Talaris Therapeutics' stock falls 21% after reporting patient death in clinical trial	Market Watch
Tuesday, 4 October 2022
07:00	Talaris Therapeutics to Present at the 2022 Cell & Gene Meeting on the Mesa	GlobeNewsWire
Wednesday, 21 September 2022
07:00	Talaris Therapeutics to Present at William Blair's Innovations in Solid Organ and Hematopoietic Stem Cell Transplant Virtual Event	GlobeNewsWire
Tuesday, 6 September 2022
07:00	Talaris Therapeutics to Participate in Two Upcoming Investor Conferences	GlobeNewsWire
Monday, 29 August 2022
07:59	Talaris Therapeutics: Plenty Of Upside Remains, But So Does The Risk	Seeking Alpha
Wednesday, 1 June 2022
07:00	Talaris Therapeutics Announces Conference Call to Highlight Presentations at the American Transplant Congress (ATC) and Provide a Data Update from its Phase 3 FREEDOM-1 Study	GlobeNewsWire
Tuesday, 31 May 2022
07:00	Talaris Therapeutics to Present at the Jefferies Healthcare Conference	GlobeNewsWire
Tuesday, 17 May 2022
16:01	Talaris Therapeutics to Present at the H.C. Wainwright Global Investment Conference	GlobeNewsWire
Tuesday, 22 March 2022
16:01	Talaris Therapeutics to Participate at Two Upcoming Investor Conferences	GlobeNewsWire
Friday, 11 February 2022
07:00	Talaris Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference	GlobeNewsWire
Thursday, 6 January 2022
07:00	Talaris Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference	GlobeNewsWire
Tuesday, 4 January 2022
07:00	Talaris Therapeutics to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference	GlobeNewsWire
Monday, 8 November 2021
07:00	Talaris Therapeutics to Participate at Three Upcoming Virtual Investor Conferences	GlobeNewsWire
Thursday, 28 October 2021
16:36	Talaris Therapeutics Announces Upcoming Presentations and Investor Conference Call During American Society of Nephrology Meeting	GlobeNewsWire

Ideas & Opinions

Seeking Alpha 29 Aug 2022

Talaris Therapeutics: Plenty Of Upside Remains, But So Does The Risk

Frequently Asked Questions (FAQ)

When is Talaris Therapeutics's next earnings date?

Unfortunately, Talaris Therapeutics's (TALS) next earnings date is currently unknown.
Does Talaris Therapeutics pay dividends?

Yes, Talaris Therapeutics pays dividends and its trailing 12-month yield is 55.58% with 0% payout ratio. The last Talaris Therapeutics stock dividend of undefined was paid on 6 Sep 2025.
How much money does Talaris Therapeutics make?

Talaris Therapeutics has a market capitalization of 116.44M. Talaris Therapeutics made a loss 68.73M US dollars in net income (profit) last year or -$0.2 on an earnings per share basis.
What is Talaris Therapeutics's stock symbol?

Talaris Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "TALS".
What is Talaris Therapeutics's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Talaris Therapeutics?

Shares of Talaris Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Talaris Therapeutics's key executives?
Talaris Therapeutics's management team includes the following people:
- Mr. Scott Requadt J.D., L.L.B., M.B.A., MBA Pres, Chief Executive Officer, Sec. & Director(age: 57, pay: $544,760)
- Dr. Suzanne T. Ildstad M.D. Founder, Chief Scientific Officer & Director(age: 72, pay: $486,070)
- Ms. Nancy Krieger M.D. Chief Medical Officer(age: 58, pay: $482,760)
Is Talaris Therapeutics founder-led company?

Yes, Talaris Therapeutics is a company led by its founder Dr. Suzanne T. Ildstad M.D..
How many employees does Talaris Therapeutics have?

As Jul 2024, Talaris Therapeutics employs 84 workers.
When Talaris Therapeutics went public?

Talaris Therapeutics, Inc. is publicly traded company for more then 4 years since IPO on 7 May 2021.
What is Talaris Therapeutics's official website?

The official website for Talaris Therapeutics is talaristx.com.
Where are Talaris Therapeutics's headquarters?

Talaris Therapeutics is headquartered at 570 South Preston Street, Louisville, KY.
How can i contact Talaris Therapeutics?

Talaris Therapeutics's mailing address is 570 South Preston Street, Louisville, KY and company can be reached via phone at +502 3989250.

Talaris Therapeutics, Inc.

talaristx.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR002 in deceased donor kidney transplants; FCR001 in patients with a severe form of scleroderma; and FCR001 for one or more severe non-malignant blood, immune, or metabolic disorders. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky.

+502 3989250

570 South Preston Street
Louisville, KY 40202

CIK: 0001827506
ISIN: US89157D1054
CUSIP: 87410C104